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ABSTRACT 
The pharmgeonetic and pharmenzymonetic factors alter plasma 
concentration of a drug achieved after the same dosage regimen in 
various individuals. Breast cancer being second most killing disease 
holds tamoxifen as a treatment of choice for years for woman. Its 
plasma concentration determines therapeutic output for that eight 
healthy female volunteers were selected from Pakistan region and 
single dose 20mg of Tamoxifen was given. After collection of blood 
samples at known intervals, plasma concentration was determined by 
high performance liquid chromatography. The maximum plasma 
concentration was 32.54±0.44 ng/mL at time 6 hours after 
administration. Mean ± SE initial tamoxifen concentration was 4.8 ± 
0.41 ng/mL and at 24 hours it was recorded as 7.4 ± 2.06 ng/mL  
 respectively. The concentration obtained was lesser than literature values proving 
geographical region dependent decrease altering therapeutic outcome and therapeutic drug 
monitoring is essential for breast cancer patients in short and for every ailment in long term. 
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INTRODUCTION 
Plasma concentration of Tamoxifen is studied widely in other countries except Pakistan. 
After the understanding of the concept of pharmenzymonetics and pharmgeonetics (Shahbaz, 
2016) the need of inculcating effect of enzymes and environment on the medicine emerged. 
Such changes in the concentration of drug achieved among the individuals of separate origins 
determine success of therapy. Our health system is negligent of the advanced treatment 
guidelines proposed by authorized bodies like WHO (Shahbaz et al., 2015), due to which an 
individual patient suffers. That is the reason chemotherapy is a question mark for the best 
treatment of breast cancer (Shahbaz et al., 2014) where one out of every 8 woman has this 
mortality causing ailment (Breast Cancer, 2013). Tamoxifen is the anti-estrogen 
chemotherapy of first line in post and pre menopausal breast cancer woman used for more 
than ten years after diagnosis of the disease. Its plasma concentration is not determined 
before in Pakistan hence data from foreign countries was used as standard which is 
unsatisfactory. Highest level of deaths has been reported due to breast cancer (Jemal et al, 
2011). It is without a doubt to research those regions which causes most noteworthy human 
passings as human life and its quality is the core interest (Shahbaz et al., 2016). 
 
It tamoxifen to estrogen receptors aggressively in tumor cells and other tissue targets, in this 
way creating an nuclear complex that abatements DNA generation and hinders estrogen 
activity. It is not a steroidal element with intense antiestrogenic properties which rival 
estrogen binding destinations in bosom and metabolized in liver by Cyp 2D6, rendering 
dynamic metabolites of tamoxifen incorporates N-desmethyl Tamoxifen, endoxifen and 4 
hydroxy Tamoxifen (Fuchs et al., 1996). It ties aggressively to estrogen receptor in such an in 
place lock, to the point that no space stays for estrogen, thus tumor development diminishes. 
Tamoxifen use comprises of ER positive breast cancer, bipolar disorder (Yildiz et al., 2008), 
infertility (Steiner et al., 2005) and gynaecomastia therefore the data about its concentration 
in the plasma of healthy Pakistani woman helps for the treatment output of all diseses for 
which this medicine is used. It is FDA approved medicine for breast cancer and recurrence 
after the removal of memory glands (FDA 2007). 
 
Pakistan imports drugs from foreign countries where environment varies considerably and the 
effect of medicine changes in pakistani individuals from leaflet values (Javed et al., 2006). 
Such effect is also explained by the concept of pharmageonetics discussing mainly the 
epigenetic factors (Shahbaz. 2016) in its consideration thus altering therapeutic results. The 
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present study was designed on eight healthy subjects namely KA, KB, KC, KD, KE, KF, KG 
and KH respectively. The plasma concentration achieved after single oral dose was 
determined through HPLC method. 
 
MATERIAL AND METHOD 
For the study of Pharmgeonetic effect on plasma concentration of Tamoxifen eight female 




Subjects of age group 35-65 years were selected after physical examination and clinical 
history to be declared as healthy. All subjects were informed about the objective of study, 




Tamoxifen, 20 mg tablet from ICI Pvt. Ltd., Lahore, Pakistan was taken. 
The following chemicals used in the entire study were of HPLC grade: 
 Ammonium acetate(Merck, Germany) 
 Acetonitrile (Fischer Scientific Limited, UK) 
 Methanol (Fischer Scientific Limited, UK) 
 Deionized water 
 
A single dose of Tamoxifen 20 mg tablet of Nolvadex brand was given orally to each subject 
after breakfast. In all experiments, a blood blank sample was collected before drug 
administration. Blood sample of 5ml each was collected from the cubital vein of each 
volunteer either directly with the help of a disposable syringe or through I.V cannula of 20 
gauge needle at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after oral dose. The pH of fresh sample 
of blood was noted in each experiment by a pH meter (Beckman HS, Germany) with a glass 
electrode at 37
0




Tamoxifen concentration in plasma samples was determined using  HPLC (Sykam, S-3210) 
analytical method using UV/Vis detector (Sykam, S-3210) (Kashtiaray et al. 2011). 
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Statistical analysis 
The mean value and standard error of mean ±SE for each concentration was calculated. Plasma 
concentration versus time data was subjected. 
 
Stock solution was prepared by dissolving 1 mg of the reference standard in 1.0 ml of HPLC-
grade methanol and mixture was diluted to 10 ml with distilled water. This stock solution was 
refrigerated at 3C⁰ for up to one week. Further 1.0mg per ml of the stock solution was diluted 
with distilled water to prepare an additional standard that was 100 nanogram per ml. 
 
Calibration standard for the plasma assay was prepared by adding 100 microliter of the 100 
nanogram per ml Tamoxifenstock solution to appropriate volume of drug-free plasma. 
Plasma Tamoxifen calibration standard curve was prepared at concentration of 0.5, 1, 2 and 4 
Nanogram per ml. 
 
The mobile phase was prepared fresh on the day of analysis by combining 75/25 v/v of 
acetonitrile and ammonium acetate (0.05M). For the adjustment of pH ammonium acetate 
was used and was filtered and degased by vacuum before use. A 200μl aliquot of the plasma 
standard was filtered to a propylene 1.5 ml snap-Cap centrifuge tube & 20μl of the working 
acetonitrile was added. The tube was vortexed at high speed for 15 second and centrifuged at 




Figure 1: Standard Curve of Tamoxifen 
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Figure 2: Chromatogram of 50 ng/ml of Tamoxifen Standard peak at right side. 
 
RESULTS 
The values of plasma concentrations of Tamoxifen in healthy adult females are determined 
which are far from plasma concentration of tamoxifen in other countries due to 
pharmgeonetic effects. 
 
Plasma concentration of the drug 
After oral administration the concentration of Tamoxifen at various time intervals for subjects 
has been presented in respective figure 4. Mean ± SE (ng/mL) values for these results are 
given in table 1. The chromatogram for various Tamoxifen concentrations at different times 
is also shown as figures 4 and 5 respectively. 
 
Table 1:  Mean ± SE Plasma Concentration (ng/ml) of Tamoxifen Following a Single 
Oral Administration 20mg In 8 Healthy Adult Female subjects 
Subject 
No. 
Time after administration (hours) 
0.5 1 2 3 4 5 6 8 12 16 24 
1 5 7 7.4 13 21 30 31.5 26 21 17.1 7.4 
2 5.1 7.1 7.6 13.5 21.6 30.5 35 26.1 20.8 9 3 
3 4.9 7 7.4 13 21.1 30 31.5 26 20.8 17.8 7.5 
4 5 7 7.4 13.1 21 30 31.7 26.9 20 17.9 7.7 
5 3 8 7.8 13.5 21.5 30.6 32.5 26 20 17.9 8 
6 5.1 7.1 7.6 13.6 21 30.9 33.2 26.1 21 17.4 9 
7 5 7 7.4 13 21 30 31.5 26 21 17.5 9.2 
8 5.9 7.6 7.6 13.1 21 30 33.4 26 21.84 17.4 9 
Mean 4.87 7.22 7.52 13.22 21.15 30.25 32.54 26.13 20.80 16.2 6.47 
±SE 0.410 0.186 0.130 0.125 0.181 0.181 0.442 0.155 0.297 0.307 0.705 
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The figure 3 dpicts graphical representation of plasma tamoxifen concentration in eight 
healthy subjects. KB reached highest level of tamoxifen in plasma and at 24 hrs concentration 
of tamoxifen decreased rapidly in KB. On the other hand overal plasma concentrationn in 
eight individuals is schematic that is lower at initial hours and reaches maximum at 5 to 6 
hours and then decreases after 8 Hrs. 
 
 
Figure 3: Plasma concentration of Tamoxifen versus time after single oral 
administration of Tamoxifen 20mg tablet in 8 healthy females. 
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Plasma concentration of Tamoxifen (Nolvadex ICI) was investigated following an oral dose 
of 20 mg tablet in eight healthy female subjects KA, KB,KC,KD,KE,KF,KG and KH 
respectively. Plasma samples were collected at different time intervals following drug 
administration, and analyzed for Tamoxifen concentration by HPLC method using 
acetonitrile and ammonium acetate 75/25 v/v as mobile phase. The mean ±SE for highest 
level of Tamoxifen in plasma was 32.54 ± 0.44 while in another study of different 
geographical region is 40ng/mL(Santana et al., 2008), 141ng/L in adults and 209ng/L in 
pediatrics (Mahra, 2005), 147ng/mL (Aman et al., 1994), 42 ng/mL (Adam et al., 1980), 
17.8ng/mL (Kashtiaray et al.,2011) and 28 ng/mL (Shahbaz et al., 2016). The possible 
variation is due to environmental effects and changed physiology of individuals belonging to 
various regions. Also various other studies were done after many doses while in current study 
single dose used for one time administration, as in another study 78ng/mL of Tamoxifen 
found in serum after 7 days of treatment (Lien et al., 1991) and serum concentration of 
83.6ng/mL after 28 days 20mg Tamoxifen treatment (Kisanga et al., 2004). 
 
Thus mean ± S.E maximum concentration of given medicine in the female subjects was 
Cmax = 32.54 ± 0.44 ng/mL achieved at 6 hours i-e. Tmax. Tmax in the present study found to 
be 6 hours may increase more than that  because drug is 99% bound to proteins  thus have a 
slower release rate (Ferner et al.,1990). 
 
One of the most interesting finding of this research is lower age and lower body weight 
(Cheymol. 2000) shows higher level of Tamoxifen in the plasma at 6 hours shown by KB 
shown in table 2. Also the KB was premenopausal and may have better water intake because 
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the drug concentration decreased rapidly to 3ng/mL, trend not observed in other subjects. 
However our study do not focus on the effect of subject characteristics on Tamoxifen plasma 
concentration and study has a short coming that by only one subject results we cannot assume 
exact impact of age and body weight on the Tamoxifen metabolism. Similarly in a trial of 
105 healthy women the Tamoxifen blood concentration was 230.6 ng/Ml after 20mg/day 
dose in two months (Decensi et al., 1999) which shows that long term use of Tamoxifen 
exceeds the plasma drug concentration in the body thus concentration obtained after single 
dose may not be therapeutic. In other words concentration gathered in months of Tamoxifen 
use may be toxic as patients are using this medicine for up to 5 years in Pakistan. Serious 
individual concerned studies regarding geographical dependent changes in the effective 
concentration of drug should be performed. 
 


















KA 53 20 72 Post Nil 31.5 6 
KB 43 20 67 Pre Nil 35 6 
KC 50 20 70 Post Nil 31.5 6 
KD 51 20 71 Post Nil 31.7 6 
KE 47 20 72 Post Nil 32.5 6 
KF 52 20 69 Post Nil 33.5 6 
KG 49 20 72 Post Nil 31.5 6 
KH 54 20 68 Post Nil 33.4 6 
 
Cyp2D6 varies in various individuals, (Jorde et al., 2004, Abraham et al., 2010) is 
metabolizer of tamoxifen to other active metabolites and its test before start of therapy is 
necessary for pharmenzymonetics study. Possible change in its concentration the body due to 
environmental change is also under consideration that favors pharmgeonetics. 
 
CONCLUSION 
Effect of geographical region and environment on the plasma concentration of Tamoxifen is 
proved with lower level of Tamoxifen found in the healthy individuals of Pakistan however it 
suggests epigenetic effects are also one of the reason when pharmgeonetics is considered. 
Importantly HPLC method was slightly modified which gave exact results in the environment 
of Pakistan for Tamoxifen on the selected chromatogram. Thusly for required level of 
Tamoxifen in blood the levels of drug dose ought to be expanded. Likewise different 
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metabolites concentration ought to be determined as Tamoxifen is a prodrug and metabolized 
to dynamic components for instance endoxifen is another research territory. 
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